| Biological functions and diseases |
Molecules |
p-value |
| Growth of tumor cell lines |
AKT1, AKT2, BAD, BCL2, BCL2L1, CAV1, CDC2, CDK2, ELK1, JUN, MAPK3, MAPK8, NF2, PTK2, RAF1, SRC, STMN1 |
1.11E-09 |
| Proliferation of tumor cell lines |
AKT1, AKT2, BAD, CAV1, GJA1, ITGB3, JUN, JUNB, LIMK1, MAPK3, MAPK8, PDPK1, SRC |
6.66E-08 |
| Anti-Apoptosis |
AKT1, AKT2, BAD, BCL2, BCL2L1, CAV1, CDC2, ITGB3, JUN, MAPK3, MAPK8, PDPK1, PTK2, SRC, STMN1, VAV1 |
4.26E-07 |
| Prostate carcinoma |
AKT1, AKT2, CDC2, CDK2, ITGB3, JUN, RAF2, SRC |
9.16E-07 |
| Metastasis |
AKT1, ITGB3, NF2, PTK2, RELA, SRC |
9.29E-07 |
| Cell cycle progression |
BCL2, CAV1, CDC25C, CDK2, MAPK8, RAF1, VAV1 |
1.85E-05 |
| Survival of tumor cell lines |
AKT1, AKT2, BCL2, BCL2L1, CAV1, CDK2, CDKN1A, CDKN1B, CHEK1, CHEK2, CREB1, EGFR, ERBB2, FRAP1, JAK1, MET, NFKB1, NFKB2, NTRK2, PDGFRB, PRKAA1, PTK2, RELA, RELB, SRC, STAT3 |
2.05E-05 |
Phosphorylation-specific antibody microarrays were used to monitor active and inactive protein levels in PC3 cells following CXCL13 stimulation. The resulting profiles were
analyzed and clustered into known biological functions and diseases to better understand the underlying mechanisms involved in CXCL13-induced signaling molecules in
prostate cancer. The p-values were calculated using Fisher’s exact test and indicate the probability of the involvement of these molecules in a given network associated
with biological functions and diseases. |
